Patents Assigned to TLC Biopharmaceuticals, Inc.
-
Patent number: 8956600Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.Type: GrantFiled: August 10, 2009Date of Patent: February 17, 2015Assignees: Taiwan Liposome Co. Ltd., TLC Biopharmaceuticals, Inc.Inventors: Sheue-Fang Shih, Po-Chun Chang, Yun-Long Tseng, Luke S. S. Guo, Keelung Hong
-
Publication number: 20140287025Abstract: The invention provides a sustained release composition for intravitreal injection to the eye of a subject in need thereof. The sustained release composition contains an effective amount of a therapeutic agent in association with a nanosphere. The nanosphere contains a particle that comprises a particle-forming component capable of forming a vesicle, and an agent-carrying component capable of forming a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction. The particle-forming component has at least one head group moiety selected from a hydrophobic head group moiety, a polar head group moiety and a combination thereof. The agent-carrying component is a chemical entity that contains one or more negatively or positively charged groups.Type: ApplicationFiled: April 9, 2014Publication date: September 25, 2014Applicants: Taiwan Liposome Company, TLC Biopharmaceuticals, Inc.Inventors: Jun-Jen LIU, Yun-Long Tseng, Sheue-Fang SHIH, Luke S.S. GUO, Keelung HONG
-
Publication number: 20140193486Abstract: The invention provides a sustained release composition for intravitreal injection to the eye of a subject in need thereof. The sustained release composition contains an effective amount of a therapeutic agent in association with a nanosphere. The nanosphere contains a particle that comprises a particle-forming component capable of forming a vesicle, and an agent-carrying component capable of forming a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction. The particle-forming component has at least one head group moiety selected from a hydrophobic head group moiety, a polar head group moiety and a combination thereof. The agent-carrying component is a chemical entity that contains one or more negatively or positively charged groups.Type: ApplicationFiled: March 7, 2014Publication date: July 10, 2014Applicants: TLC Biopharmaceuticals, Inc., Taiwan Liposome CompanyInventors: Jun-Jen LIU, Yun-Long Tseng, Sheue-Fang SHIH, Luke S.S. GUO, Keelung HONG
-
Patent number: 8753673Abstract: The invention provides a liposome composition for delivering high pay-load of a therapeutic agent to neovascularization sites of the eyes in a patient in need thereof. The liposome composition for entrapping the therapeutic agent comprises a particle forming component composed of a variety of vesicle-forming lipids, and an agent-carrying component able to form a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction; wherein the liposome composition comprising the therapeutic agent has a mean particle diameter of about 30 to 200 nm and may accumulate at the neovascularization sites of the eyes 24 hours after the intravenous administration of the liposome composition comprising the therapeutic agent to the patient. A method for delivering the therapeutic agent to the eyes in a patient with this liposome composition is also provided.Type: GrantFiled: May 23, 2006Date of Patent: June 17, 2014Assignees: Taiwan Liposome Co. Ltd., TLC Biopharmaceuticals, Inc.Inventors: Jun-Jen Liu, Chi-Chun Lai, Yun-Long Tseng, Luke S. S. Guo, Keelung Hong
-
Publication number: 20140135357Abstract: The present invention is directed to a method of inhibiting cancer cell growth, comprising administering a pharmaceutical composition to a subject in need thereof. The pharmaceutical composition comprises at least one camptothecin derivative or a pharmaceutically acceptable salt thereof; and at least one PEG phospholipid, and provides a sustained release of topotecan as an active ingredient.Type: ApplicationFiled: November 12, 2013Publication date: May 15, 2014Applicants: Taiwan Liposome Company, Ltd., TLC Biopharmaceuticals, Inc.Inventors: Yun-Long TSENG, Keelung HONG, Min-Wen KUO
-
Patent number: 8168648Abstract: The present invention provides two new camptothecin derivatives, which were identified as S,R- and S,S-topotecan lactates, respectively. Both compounds have anticancer activities. Pharmaceutical compositions of the new camptothecin derivatives, and cancer therapies with the new camptothecin derivatives or their pharmaceutical compositions were also provided.Type: GrantFiled: March 5, 2010Date of Patent: May 1, 2012Assignees: Taiwan Liposome Co., Ltd., TLC Biopharmaceuticals, Inc.Inventors: Min-Wen Kuo, Yung-Hsu Chan, Yun-Long Tseng, Siong-Tern Liew, Keelung Hong
-
Publication number: 20100227877Abstract: The present invention provides two new camptothecin derivatives, which were identified as S,R- and S,S-topotecan lactates, respectively. Both compounds have anticancer activities. Pharmaceutical compositions of the new camptothecin derivatives, and cancer therapies with the new camptothecin derivatives or their pharmaceutical compositions were also provided.Type: ApplicationFiled: March 5, 2010Publication date: September 9, 2010Applicants: Taiwan Liposome Co. Ltd., TLC Biopharmaceuticals, Inc.Inventors: Min-Wen Kuo, Yung-Hsu Chan, Yun-Long Tseng, Siong-Tern Liew, Keelung Hong
-
Patent number: 7740844Abstract: The present invention provides novel monoclonal antibodies with a high binding affinity to all five isoforms of human VEGF.Type: GrantFiled: April 29, 2008Date of Patent: June 22, 2010Assignees: Taiwan Liposome Co. Ltd, TLC Biopharmaceuticals, Inc.Inventors: Keelung Hong, Luke S. S. Guo, Yun-Long Tseng, Hsiu-Li Song, Po-Chun Chang, Sheue-Fang Shih
-
Publication number: 20090269336Abstract: The present invention provides novel monoclonal antibodies with a high binding affinity to all five isoforms of human VEGF.Type: ApplicationFiled: April 29, 2008Publication date: October 29, 2009Applicants: Taiwan Liposome Co. Ltd, TLC Biopharmaceuticals, Inc.Inventors: Keelung Hong, Luke S.S. Guo, Yun-Long Tseng, Hsiu-Li Song, Po-Chun Chang, Sheue-Fang Shih
-
Publication number: 20080234376Abstract: An emulsion composition includes prostaglandin E1 (PGE1), a phospholipid with a high purity and a non-proton-providing surfactant that improves stability of PGE1. Embodiments of the emulsion composition include an effective amount of PGE1, about 1% to about 30% (w/w) of a pharmaceutically acceptable oil as an oil base based on the weight of the emulsion composition, about 1% to about 30% (w/w) of a phospholipid with a high purity based on the weight of the oil base, about 1.6% to about 40% (w/w) of a non-proton-providing surfactant based on the weight of the oil base, and the balance of the emulsion composition being water.Type: ApplicationFiled: August 15, 2007Publication date: September 25, 2008Applicants: TAIWAN LIPOSOME COMPANY (A TAIWAN CORPORATION), TLC Biopharmaceuticals, Inc. ( a United States business entity)Inventors: Yi-Fong LIN, Pei KAN, Keelung HONG
-
Publication number: 20080118500Abstract: The invention provides a sustained release composition for intravitreal injection to the eye of a subject in need thereof. The sustained release composition contains an effective amount of a therapeutic agent in association with a nanosphere. The nanosphere contains a particle that comprises a particle-forming component capable of forming a vesicle, and an agent-carrying component capable of forming a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction. The particle-forming component has at least one head group moiety selected from a hydrophobic head group moiety, a polar head group moiety and a combination thereof. The agent-carrying component is a chemical entity that contains one or more negatively or positively charged groups.Type: ApplicationFiled: November 16, 2007Publication date: May 22, 2008Applicants: Taiwan Liposome Company, TLC Biopharmaceuticals, Inc.Inventors: Jun-Jen Liu, Yun-Long Tseng, Sheue-Fang Shih, Luke S.S. Guo, Keelung Hong
-
Publication number: 20070275048Abstract: The invention provides a liposome composition for delivering high pay-load of a therapeutic agent to neovascularization sites of the eyes in a patient in need thereof. The liposome composition for entrapping the therapeutic agent comprises a particle forming component composed of a variety of vesicle-forming lipids, and an agent-carrying component able to form a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction; wherein the liposome composition comprising the therapeutic agent has a mean particle diameter of about 30 to 200 nm and may accumulate at the neovascularization sites of the eyes 24 hours after the intravenous administration of the liposome composition comprising the therapeutic agent to the patient.Type: ApplicationFiled: May 23, 2006Publication date: November 29, 2007Applicants: TAIWAN LIPOSOME CO. LTD., TLC BIOPHARMACEUTICALS, INC.Inventors: Jun-Jen LIU, Chi-Chun Lai, Yun-Long TSENG, Luke S.S. GUO, Keelung HONG